Specifically, in gastric cancer, higher ZNF521 expression was correlated with worse OS in stage II and stage IV patients, PFS in stage II and stage III patients, PPS in stage II, III, and IV patients, but was not associated with OS, PFS, or PPS in stage I patients or OS and PFS in stage N0 patients. The gene discussed is ZNF521; the disease is gastric cancer.